CLINICAL TRIAL

Treatment for Hematologic Neoplasms

Recruiting · 18+ · All Sexes · Santa Monica, CA

This study is evaluating whether belinostat may have positive impacts for individuals with cancer.

See full description

About the trial for Hematologic Neoplasms

Eligible Conditions
Hematologic Neoplasms · Tumors, Solid · Haematological Malignancies

Treatment Groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The patient agrees to continue receiving belinostat treatment as originally outlined in the clinical study protocol. show original
The patient must be willing to give written consent and be able to adhere to dosage and visit schedules and meet study requirements. show original
The investigator believes that the extended treatment with belinostat is appropriate for the patient, and the patient is suited for the treatment. show original
The patient has completed a Spectrum-sponsored clinical study using belinostat show original
The patient is willing to use two methods of contraception, one of which must be a barrier method, from the start of the study until at least 30 days after the last dose of the study drug. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 35 (±5) days after the last dose of belinostat
Screening: ~3 weeks
Treatment: Varies
Reporting: 35 (±5) days after the last dose of belinostat
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 35 (±5) days after the last dose of belinostat.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Hematologic Neoplasms. Measurement will happen over the course of 35 (±5) days after the last dose of belinostat.

Evaluation of safety include assessment of all SAEs, and all deaths on study or within 35 (±5) days of last study treatment
35 (±5) DAYS AFTER THE LAST DOSE OF BELINOSTAT
Frequency of adverse events (AEs & serious adverse events (SAEs)
35 (±5) DAYS AFTER THE LAST DOSE OF BELINOSTAT

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can hematologic neoplasms be cured?

Hematologic neoplasms are highly curable depending upon stage at diagnosis and the degree of pre-treatment disease. Hematological malignancies are better treated than their benign counterparts in most cases.

Anonymous Patient Answer

What causes hematologic neoplasms?

Hematologic neoplasms are most probably due to a multifactorial combination of environmental, immunological, genetic and other causative factors. However, hematological neoplasms have common features that can help in the clinical diagnosis and in understanding their pathogenesis.

Anonymous Patient Answer

What are common treatments for hematologic neoplasms?

Chemotherapy and radiotherapy are the treatments of choice for almost all forms of cancer; both are used for more aggressive and advanced disease. The chemotherapy regimen may change over time as newer agents of induction and/or consolidation are developed and implemented, as demonstrated in the treatments discussed below. New approaches to chemotherapy in leukemia and lymphoma remain under investigation.

Anonymous Patient Answer

How many people get hematologic neoplasms a year in the United States?

A small but measurable number of people in the United States, around 8 in 100,000, receive hematologic neoplasms a year. Of particular relevance, 1 in 3 men are carriers of a genetic predisposition to develop these malignancies. Most common of these are B-cell lymphomas, mainly leukemia and multiple myeloma, and, to a lesser extent, Hodgkin's disease and non-Hodgkin's lymphoma.

Anonymous Patient Answer

What are the signs of hematologic neoplasms?

Symptoms of leukemias and lymphomas are usually nonspecific. In contrast with solid tumors, symptoms from hematologic neoplasms are not typically alarming in an unselected patient population. Although patients with myeloproliferative neoplasms and lymphomas are prone to increased discomfort resulting from the growth of the neoplasm, other signs are more often present when the disorder is in their early phases. Hemoglobin and erythropoietin levels are often elevated as a result of hemoglobin synthesis.

Anonymous Patient Answer

What is hematologic neoplasms?

Hematologic neoplasms occur from the abnormal growth of blood or bone marrow cells. Hematologic neoplasms are grouped under several histologic types and include leukemia, lymphoma, multiple myeloma and multiple bone tumors. Cancer is often difficult to recognize early. Most patients with the disease have either poor or no control of the disease at the time of diagnosis or before referral. About one third of patients will die from the disease within two years of diagnosis. The best overall outcome is for acute lymphoblastic leukemia when it was definitively diagnosed, whereas most patients will die when their disease becomes unrecognized and undiagnosed.

Anonymous Patient Answer

What are the chances of developing hematologic neoplasms?

These studies demonstrate that both patients undergoing RT and patients with the LFSR are at risk for developing a cancer of the blood or blood-forming system.

Anonymous Patient Answer

Who should consider clinical trials for hematologic neoplasms?

Most adults with advanced neoplasia will require a clinical trial. The need for a clinical trial is most commonly for patients whose disease has progressed following standard therapy.

Anonymous Patient Answer

What are the common side effects of treatment?

Patients treated with chemotherapy for myeloma may experience a variety of side effects. These side effects are not necessarily necessarily a reflection of the underlying cause or a surrogate marker for disease progression. The most common side effects of chemotherapy reported in this population are febrile neutropenia, peripheral neuropathy, anemia, and pulmonary toxicity. Symptoms usually manifest within 3 to 12 weeks after commencing chemotherapy. The development of aseptic meningitis is a common complication of high doses of cisplatin. In the current study, the incidence of aseptic meningitis in patients receiving cisplatin was 0% (6/637). The most common side effect of thalidomide treatment is peripheral neuropathy.

Anonymous Patient Answer

What is treatment?

The treatment of choice is often determined by factors such as the risk to the patient, the risk to the clinician with respect to malpractice suits, and the cost-benefit of the treatment. For example, if there are concerns about the risk of life-threatening bleeding, then therapies that involve the risk of this are not recommended.

Anonymous Patient Answer

What is the latest research for hematologic neoplasms?

In recent years, the researchers are increasingly more concerned about the epigenetic modification of tumor cells, which, in conjunction with the existing mutations, causes tumor cell proliferation, growth, and the development of metastases. Many authors insist on the necessity of the epigenetic modification and metastasis of tumor in the treatment of disease and prevention of metastasis. The combination of these two characteristics is most significant to understand the progress of the disease pathogenesis, metastasis, and treatment by the use of medications. Recent findings have become more and more remarkable and promising research for hematologic neoplasms. A wide variety of drugs is prescribed to control the disease and to prevent tumors development and metastasis.

Anonymous Patient Answer

What is the primary cause of hematologic neoplasms?

The major risk factor for these two types of malignancies is occupational exposure to ionizing radiation, particularly nuclear fallout during nuclear weapons testing. The relative risk of leukemia is high and is the highest between 1 and 10 Bq/m. The most common type of leukemia associated with ionizing radiation exposure is chronic myeloid leukemia and the second is acute lymphoblastic leukemia. Exposure to low doses of radiation below 5 mR or low doses of radiation plus a weak and transient exposure to high doses appears not to increase the risk.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Hematologic Neoplasms by sharing your contact details with the study coordinator.